Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784218 | 0.96 | SLC6A9 (0.40) | CTSSTAS1R3TAS1R1TAS1R2SLC6A9 | |
| SCHEMBL784955 | 0.91 | TAS1R3 (0.44) | CTSSTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL784793 | 0.90 | TAS1R3 (0.45) | CTSSTAS1R3TAS1R1TAS1R2TRPV1 | |
| SCHEMBL785316 | 0.88 | CTSS (0.42) | CTSSTRPV1ALDH1A1SLC2A1WDR5 | |
| SCHEMBL784203 | 0.88 | ALDH1A1 (0.51) | CTSSTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL27902569 | 0.88 | WDR5 (0.40) | CTSSSLC2A1WDR5PDK2AURKA | |
| SCHEMBL785552 | 0.88 | WDR5 (0.40) | CTSSSLC2A1WDR5PDK2AURKA | |
| SCHEMBL784227 | 0.88 | ALDH1A1 (0.51) | CTSSTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL784439 | 0.87 | SLC6A9 (0.40) | SLC6A9PDK2 | |
| SCHEMBL785312 | 0.87 | P2RX7 (0.39) | SLC6A9PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CTSS 824/4885TAS1R3 202/4885TAS1R1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.